Adult acute respiratory distress syndrome
Therapeutic area
Pulmonology
Rare disease
Yes
- Definition
- A very severe form of acute pulmonary failure secondary to capillary permeability impairment. The symptoms include dyspnea, hypotension and multivisceral failure. The disease is characterized by bilateral pulmonary infiltrates and severe hypoxemia due to increased alveolar-capillary permeability. The severity depends on the degree of alveolar epithelial injury, with a mortality rate of 30-50%.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Adult acute respiratory distress syndrome
- Therapeutic area
- Pulmonology
- adult acute respiratory distress syndrome
- adult ARDS
- adult acute respiratory distress syndrome
- adult respiratory distress syndrome
- adult respiratory distress syndrome, ARDS
- respiratory distress syndrome, adult
- ARDS
- Disease mechanisms
- Syndromic
- All therapeutic areas
- Pulmonology
- Severity
- Severe
- MONDO ID
- MONDO:0100130
- Parent condition
- MONDO:0006502
Related records
Broader conditions (11)
- Acute disease
- Acute respiratory distress syndrome
- Acute respiratory failure
- Disease
- Disease by body system or component
- Human disease
- Lower respiratory tract disorder
- Lung disorder
- Respiratory failure
- Respiratory system disorder
- Syndromic disease
Trials (590)
- "Effects of Neuromuscular Blocking Agents on End Expiratory Lung Volume During Moderate-severe ARDS"
- A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
- A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS
- A Comparison of Optimal PEEP Determination Guided by EIT and Conventional Protective Ventilation Tool in ARDS Patients
- A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
- A First-in-Human Study of AV-001 in Healthy Subjects
- A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
- A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)
- A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury
- A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS
- A Prospective Clinical Study to Explore Response to Prone Positioning in ARDS Patients
- A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.
- A Randomized Trial of GM-CSF in Patients With ALI/ARDS
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19
- A Real World Study of Respiratory Critical Disease.
- A Reverification of the Berlin Definition Plateau Criteria in Golmud
- A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
- A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
- A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients
Approved drugs (1)
- Calfactant
Drugs in development (21)
- Albuterol sulfate Phase 2
- Alprostadil Phase 2
- BIO-11006 Phase 2
- Carbon monoxide Phase 2
- Dexamethasone Phase 3
- Dornase alfa Phase 3
- Drotrecogin alfa (activated) Phase 2
- GSK-1995057 Phase 1
- Hydroxychloroquine Phase 3
- IC14 Phase 2
- Iloprost Phase 3
- Interferon beta-1A Phase 3
- Ketoconazole Phase 3
- Methylprednisolone Phase 3
- Plasmalyte A Phase 2
- Regramostim Phase 2
- Reparixin Phase 2
- Roflumilast Phase 2
- Sabizabulin Phase 2
- Sodium chloride Phase 2
Other linked drugs (2)
- Spironolactone
- Vilobelimab